AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts

July 31, 2017, Gaithersburg, Md., AstraZeneca and MedImmune, its global biologics research and development arm, today announced the appointment of two internationally-recognised immuno-oncology leaders. Dr. Jean-Charles Soria joins MedImmune as Senior Vice President, Head of Oncology Innovative Medicines, and Dr. Geoffrey Kim has been appointed as Head of Oncology Strategic Combinations at AstraZeneca.

Dr. Bahija Jallal, Executive Vice President, MedImmune, said: “AstraZeneca and MedImmune are delighted to welcome Dr. Soria and Dr. Kim. Our ability to attract these recognised experts in the fast-developing field of immuno-oncology speaks to our exciting pipeline of innovative cancer treatments and our commitment to pushing the boundaries of science.”

Dr. Jean-Charles Soria

Dr. Soria will lead a team at MedImmune responsible for the strategy, growth, and advancement of the early oncology biologics portfolio, which includes oncology research, translational medicine, and early oncology development.

As a medical oncologist and scientist, Dr. Soria has made substantial research contributions toward potential therapeutic treatments for cancer throughout his career, especially in immuno-oncology. Prior to joining MedImmune, Dr. Soria served as a Professor of Medicine and Medical Oncology at South-Paris University – one of the largest and most renowned French universities. He was also a tenure-track and full-time cancer specialist at the Institut Gustave Roussy – one of the world’s leading cancer-research institutes and the premier European Cancer Center. There, he served as Chair of the Drug Development Department and a member of the lung cancer unit with a focus on targeted therapies.

Dr. Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree summa cum laude in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, where he has held an Adjunct Professorship since 2012.

Dr. Soria will join in early September and succeed Dr. David Berman, who has been appointed to the new and expanded role of Senior Vice President, Immuno-oncology Franchise.

Dr. Geoffrey Kim

Dr. Geoffrey Kim and his team will focus on the development of the company’s late-stage immuno-oncology combinations programme with the ultimate goal of developing combination regimens that will deliver innovative medicines to patients.  

Dr. Kim was most recently with the US Food and Drug Administration (FDA) where he had an impressive tenure serving as the Director, Division of Oncology Products in the Office of Haematology Oncology Products since 2015. In this role, he was tasked with the evaluation and regulation of oncology drug products that were in development and approved for breast, genitourinary, and gynecologic cancers. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimisation strategies for cancer medicines. Dr. Kim began working at the FDA in 2010 as a Medical Officer in the Division of Oncology Products.

He received his bachelor’s degree at UCLA, his medical degree at the New York Medical College, and completed his residency in internal medicine at the Montefiore Medical Center. He performed laboratory research at these institutions with a particular focus on cell adhesion molecules and cellular signaling. Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signalling and ovarian cancer.

Dr. Kim started at the company 17 July 2017.  

Both Dr. Soria and Dr. Kim will be based in Gaithersburg, Md., one of AstraZeneca’s three global strategic R&D centres and MedImmune headquarters.

About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Contact
Rebecca Einhorn, einhornr@medimmune.com, +1 301 398-1802